Results 31 to 40 of about 61,821 (357)

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

Pharmaceutics, 2022
Advancement in sequencing technologies allows for the identification of molecular pathways involved in tumor progression and treatment resistance.
Luigi Liguori, Giovanna Polcaro, Annunziata Nigro, Valeria Conti, Carmine Sellitto, Francesco Perri, Alessandro Ottaiano, Marco Cascella, Pio Zeppa, Alessandro Caputo, Stefano Pepe, Francesco Sabbatino   +11 more
doaj   +1 more source

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]

, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald, Fenn, Sebastian, Gassner, Christian, Griese, Julia J., Hopfner, Karl-Peter, Imhof-Jung, Sabine, Kettenberger, Hubert, Klein, Christian, Moelleken, Joerg, Regula, Joerg Thomas, Schaefer, Wolfgang, Schiller, Christian B., Thomas, Markus   +12 more
core   +3 more sources

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies [PDF]

, 2013
Background Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2.
A Formentini, A Pfosser, A Thakur, A Thakur, A Thakur, A Yamauchi, AB Heimberger, Archana Thakur, AT Ogden, BF Skinnider, G Jung, GA Niehans, Geoffrey R Barger, HE Lum, Ian M Zitron, J O’Connell, JF Mineo, JK Chan, JM Gall, K Ohshima, K Shiraki, KO Nam, L Davico Bonino, L Ren-Heidenreich, Lawrence G Lum, LG Lum, LM Weiner, M Al-Hajj, M Hahne, M Hishii, M Kawakami, M Sen, M Yankelevich, N Husain, Oxana Norkina, P Saas, PA Davol, RC Grabert, RO Dillman, Sandeep Mittal, SK Jacobs, SK Singh, T Hida, T Nishimura, T Nishimura, T Nitta, TA Dolecek, U Kapp, U Reusch, V Kolenko, X Yuan, Y Oshima   +51 more
core   +4 more sources

Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting

Molecules, 2019
A promising strategy in cancer immunotherapy is the employment of a bispecific agent that can bind with both tumor markers and immunocytes for recruitment of lymphocytes to tumor sites and enhancement of anticancer immune reactions.
Zhaoyi Li, Yan Hu, Yacong An, Jinhong Duan, Xundou Li, Xian-Da Yang   +5 more
doaj   +1 more source

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds [PDF]

, 2017
Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit ...
Abhishek Saxena, Donghui Wu, Hongyan Liu, Sachdev S. Sidhu   +3 more
core   +1 more source

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Journal of Blood Medicine, 2021
Robert Klamroth,1 Piotr Wojciechowski,2 Samuel Aballéa,3 Françoise Diamand,4 Zalmai Hakimi,5 Jameel Nazir,5 Lydia Abad-Franch,6 Stefan Lethagen,7 Elena Santagostino,8 Michael D Tarantino9 1Department of Internal Medicine, Hemophilia ...
Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD   +9 more
doaj  

Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

Frontiers in Oncology, 2020
This perspective highlights the history and challenges of developing CD3-based bispecific T-cell engagers (TCEs) as cancer therapeutics as well as considerations and potential strategies for designing the next generation TCE molecules.
Omid Vafa, Nathan D. Trinklein
doaj   +1 more source

Identification and characterization of nanobodies targeting the EphA4 receptor [PDF]

, 2017
The ephrin receptor A4 (EphA4) is one of the receptors in the ephrin system that plays a pivotal role in a variety of cell-cell interactions, mostly studied during development. In addition, EphA4 has been found to play a role in cancer biology as well as
Chavez-Gutierrez, Lucia, Curnock, Adam, De Strooper, Bart, Dewilde, Maarten, Hassanzadeh-Ghassabeh, Gholamreza, Haustraete, Jurgen, Joyce, Peter, Lemmens, Robin, Little, Susan, Robberecht, Wim, Roucourt, Bart, Rue, Laura, Schoonaert, Lies, Timmers, Mieke, Van Damme, Philip, Van den Bosch, Ludo, Weber, Peter   +16 more
core   +2 more sources

Design and engineering of bispecific antibodies: insights and practical considerations

Frontiers in Bioengineering and Biotechnology
Bispecific antibodies (bsAbs) have attracted significant attention due to their dual binding activity, which permits simultaneous targeting of antigens and synergistic binding effects beyond what can be obtained even with combinations of conventional ...
Andreas V. Madsen, Lasse E. Pedersen, Peter Kristensen, Steffen Goletz   +3 more
doaj   +1 more source